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Abstract
Background: Secondary lymphedema is common in women treated for breast cancer. It may be a result of surgery
or radiotherapy. Edema commonly affects the arm, leading to discomfort, reduced arm movements, pain and diminished
quality of life. Therefore, the relationship between post mastectomy lymphedema and quality of life has evolved as an
important criteria in treatment of breast cancer survivors.
Methods: Sixty breast cancer survivors who developed post mastectomy lymphedema were recruited. Patients were
divided into 2 groups (n = 30) according to the treatment they received; Conventional therapy (CT) and Complete
Decongestive Therapy (CDT) groups. Measurements were taken at baseline, 4 and 6 weeks. Health related Quality of Life
was evaluated with the EORTC QLQ C30 and EORTC QLQ-BR23 questionnaires. Pain was measured using the Visual
Analogue Scale. Descriptive statistics were used to analyze participant demographics and repeated measures of ANOVA
was used for within and between group comparisons.
Results: Both groups showed improved quality of life and diminished pain after 6 weeks of treatment. However, greater
improvement was observed in CDT group compared to the CT group.
Conclusion: In this study, remedial exercises and home program in addition to manual lymphatic drainage and
compression bandaging resulted in improved quality of life. Early identification of lymphedema and incorporation of
remedial exercises and a home program improve the quality of life for breast cancer survivors.
Trial registration: Trial registry ID: ISRCTN13242080, Date of registration: 7 April 2016
Keywords: Health related quality of life, Functional status, Post mastectomy lymphedema
Background
Health related quality of life (HRQOL) of patients is a
topic of growing interest. HRQOL reflects the impact of
disease and its treatment on functional health status
(i.e., limitations in physical, psychological and social
functioning) and global wellbeing [1]. Post mastectomy
lymphedema (PML) is frequently encountered by breast
cancer patients which in turn leads to poor functional
recovery, chronic disability and impaired quality of life
[2–4]. Women with arm edema secondary to breast
cancer therapy may suffer from psychological morbidity
such as anxiety and depression, functional and physical
impairment, and diminished quality of life [5–7] Breast
cancer symptoms, type of surgical intervention, adjuvant
therapies and women’s economic level are directly asso-
ciated with Health-Related Quality of Life [8–11]. Breast
cancer survivors may find lymphedema more distressing
than mastectomy, because hiding the physiological man-
ifestations and loss of function is harder which in turn
leads to decreased quality of life [12–16].
Several therapeutic interventions exist to treat this
potentially distressing and disabling condition, but no
consensus has been reached as to what constitutes optimal
or definitive treatment of lymphedema [12, 13]. Complete
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decongestive therapy is considered the mainstay of lymph-
edema treatment. It consists of 4 components- 1) Manual
lymphatic drainage (MLD), 2) compression bandaging, 3)
exercises to enhance lymphatic drainage, and 4) skin care
[17, 18]. MLD was developed in 1930s by Dr. Emil Vodder.
It is a unique massage technique which uses specific hand
movements to provide a gentle pumping action on the skin.
The gentle, rhythmic, pumping, massage movements follow
the direction of lymph flow and produce rapid results. This
ensures that the maximum skin stretching effect is gained
with the minimum of pressure. As a result, lymph flow im-
proves without increasing capillary filtration [19].
MLD has been shown to have a number of physiological
effects which include an increase in the contraction rate
of lymph, increased reabsorption of proteins, reduced
micro lymphatic hypertension and improved collateral
lymph drainage between the lymphatic territories of the
skin. Improved drainage enables fluid to be redirected
away from edematous areas towards the functioning lymph
nodes in unaffected areas, an important principle in
lymphedema management [20, 21]. Patients’ education
and self -care is important and considered critical for
successful long-term effects. Clinicians require evidence
to support the intensity of initial intensive treatment as
well as the importance of each component of CDT. Im-
provements in the treatment of breast cancer have led to
increased survival rates and increased emphasis on im-
proving outcomes and quality of life through targeted re-
habilitation [22, 23]. The evidence from cross-sectional
and longitudinal studies on patients with lymphedema
showed poor psychological adjustment, greater deficits in
their ability to function physically and socially and in-
creased anxiety and depression [7]. Several valid instru-
ments exists to measure quality of life in breast cancer
patients. The European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) [24–27] and its breast cancer spe-
cific complementary measure (EORTC QLQ-BR23)
[28–35], and the Functional Assessment Cancer Therapy
General questionnaire (FACT-G) and its breast cancer
module (FACT-B), are found to be the most common and
well developed instruments to measure quality of life in
breast cancer patients [36–38]. EORTC QLQ C30 consists
of 30 functional, symptom and individual items de-
signed to address a wide range of QOL issues relevant
to a broad spectrum of cancer [24, 39]. EORTC QLQ-
BR23 is also a reliable and valid supplementary measure
of the quality of life in breast cancer patients and can
be used in clinical trials and oncology studies [40].
Studies of quality of life can further indicate the direc-
tions needed for more efficient treatment of post mast-
ectomy lymphedema. The aim of this study is to
evaluate the effect of adding an exercise component
and a home program to Complete Decongestive
Therapy (CDT) on Health related quality of life in post-
mastectomy lymphedema patients.”
Methods
This is a mixed factorial design that includes both be-
tween and within subjects variables. Eighty subjects
were screened and 20 individuals were excluded as
they did not meet the inclusion criteria. A power ana-
lysis indicated that 27 participants per group would
provide 80 % power to detect a treatment effect of 0.5.
Sixty participants were divided into two groups: con-
ventional treatment (CT) group and complete decon-
gestive therapy (CDT) group. Each group comprised
of 30 participants with a mean age of 56.3 ± 3.3 years
and 56 ± 3.5 years respectively. Recruitment was done
from Maharishi Markendeshwar University hospital.
Participants’ were aged between 50 and 70 years, who
had unilateral mastectomy for stage I and II breast
cancer. They completed the radiotherapy and chemo-
therapy sessions. Arm circumferences were measured
using a cloth measuring tape at four levels: the meta-
carpophalangeal joints, wrist joint, 15 cm distal to the
lateral epicondyle, and 10 cm proximal to the lateral
epicondyle. Arm volume was calculated using the for-
mula” V = h (C12 + C1C2-C22)/12π2”. Subjects who
developed lymphedema more than 3 cm compared to
contralateral extremity were included. Participants
with primary lymphedema, bilateral lymphedema, pulmon-
ary edema, congestive heart failure or any contraindications
limiting therapy were excluded. The purpose and procedure
of the study was explained to all the participants. A signed
informed consent was taken. Maharishi Markendeshwar
University ethical committee approved the study. System-
atic random sampling procedure was used to include the
participants into the study. Data was collected every
Monday and Wednesday from the physical therapy out-
patient clinic. “Volunteer participants assessed on Monday
were assigned to the CT group, whereas participants
assessed on Wednesday were assigned to the CDT group.
Demographic characteristics such as education level,
marital status, type of surgery, and affected arm are pre-
sented in Table 1. The majority of the participants were
literate and married. Lymphedema was observed in both
dominant and non-dominant upper limbs. There were no
significant differences in the demographic characteristics
between the groups (p <0.05).
Procedure
Conventional therapy (CT) group participants received
manual lymphatic drainage, low elastic compression
garment, gleno-humeral mobilization and deep breath-
ing exercises. Massage strokes were applied to the side
of the edematous limb, starting at the base of the neck
and progressing to the affected limb. Massage was always
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directed proximally from the upper arm to the axilla, and
then from the hand to the elbow. Finally, the whole limb
was massaged from the distal to the proximal portion. CDT
group received manual lymphatic drainage, compression
garment worn 23 h daily, remedial exercises and a home
program. Both groups received treatment 5 times a week
for 6 weeks. CDT group participants and occasionally
family members received training in self –massage.
They were encouraged to do self -lymph drainage at
least once daily. Remedial exercises were given with
diaphragmatic breathing exercises in between. The fol-
lowing order was adopted for remedial exercises by a
trained physiotherapist: 1) warm up activity by active
mobilization of large joints at moderate pace for
5 min; 2) shoulder girdle mobilization-scapular retraction,
protraction, depression, shoulder extension, elbow flexion
and extension, wrist flexion and extension and ball squeeze;
3) Pectorals and trapezius muscles stretching. The patients
were comfortably seated, relaxed, placed their hands over
their abdominal muscles, and took deep breaths through
the nose and a prolonged expiration through mouth with-
out any strenuous effort (diaphragmatic breathing). The 1 h
home program involved self -lymphatic drainage, skin care
and the remedial exercises. Participants received booklets






t Value Sig.(p value)
Age (Years) 56.3 ± 3.3 56 ± 3.5 0.34 0.7*
Educational level Literate 25 (42 %) 27 (45 %) 0.14 0.7*
Illiterate 5 (8 %) 3 (5 %)
Marital status Single 4 (7 %) 5 (8 %) 0.13 0.7*
Married 26 (43 %) 25 (42 %)
Type of surgery Radical Mastectomy 17 (43 %) 18 (45 %) 0.22 0.6*
Modified Radical Mastectomy 3 (8 %) 2 (5 %)
Affected Arm Dominant 15 (38 %) 14 (35 %) 0.12 0.7*
Non Dominant 5 (13 %) 6 (15 %)
M mean, SD standard deviation, t- value independent t test, *Not significant at P ≤0.05
Table 2 Values of outcome measures by treatment group and time of measurement
CDT CT
Outcome measure Time of measurement Mean ± SD (95 % CI) Mean ± SD (95 % CI)
VAS Baseline 6.87 ± 0.94 (6.52–7.22) 6.90 ± 1.09 (6.49–7.31)
4th Week 3.17 ± 0.87 (2.84–3.49) 4.53 ± 1.07 (4.13–4.93)
6th Week 1.40 ± 0.50 (1.21–1.59) 2.93 ± 0.87 (2.61–3.26)
EORTC QLQ C30 Global scale Baseline 39.60 ± 4.74 (37.83–41.37) 39.63 ± 4.71 (37.81–41.39)
4th Week 41.9 ± 4.72 (40.14–43.66) 40.57 ± 4.72 (38.80–42.33)
6th Week 49.13 ± 5.49 (47.08–51.18) 41.57 ± 4.72 (39.80–43.33)
EORTC QLQ C30 Functional scale Baseline 79.93 ± 1.41 (79.41–80.46) 79.93 ± 1.41 (79.41–80.46)
4th Week 83.27 ± 1.98 (82.53–84.01) 80.87 ± 1.36 (80.36–81.37)
6th Week 85.27 ± 1.98 (84.53–86.01) 81.83 ± 1.42 (81.30–82.36)
EORTC QLQ C30 Symptoms scale Baseline 40.93 ± 3.26 (39.72–42.15) 40.93 ± 3.26 (39.72–42.15)
4th Week 44.07 ± 3.42 (42.79–45.34) 41.93 ± 3.26 (40.72–43.15)
6th Week 47.07 ± 3.51 (45.75–48.38) 42.90 ± 3.32 (41.66–44.14)
EORTC QLQ BR23 Functional scale Baseline 32.20 ± 2.11 (31.41–32.99) 32.20 ± 2.11 (31.41–32.99)
4th Week 36.37 ± 2.54 (35.42–37.31) 33.20 ± 2.11 (32.41–33.99)
6th Week 38.13 ± 2.71 (37.12–39.15) 34.17 ± 2.20 (33.35–34.99)
EORTC QLQ BR23 Symptoms scale Baseline 58.67 ± 2.34 (57.79–59.54) 58.67 ± 2.34 (57.79–59.54)
4th Week 62.33 ± 2.52 (61.39–63.28) 59.67 ± 2.34 (58.79–60.54)
6th Week 62.63 ± 7.99 (59.55–65.52) 60.63 ± 2.40 (59.74–61.53)
CT conventional therapy, CDT complete decongestive therapy, VAS visual analogue scale, SD standard deviation, CI confidence interval
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on the home program after initial education and training
about home exercises. They were requested to keep a log
for their home program. Both groups were treated for
6 weeks. Pain and QOL were assessed at baseline, 4th
and 6th week of treatment.
The EORTC (European Organization of Research and
Treatment for Cancer) QLQ-C30 version 3.0 is a 30-item
core cancer specific questionnaire measuring QOL in
cancer patients. This self-administered questionnaire
incorporates five functional scales: Physical (PF), role
(RF), cognitive (CF), emotional (EF) and social (SF), three
symptom scales for fatigue, pain and nausea/vomiting, a
global health QOL scale, and several single items for the
perceived financial impact of disease and treatment and
for the assessment of additional symptoms such as dys-
pnea, appetite loss, sleep disturbance, constipation and
diarrhea which are commonly reported by cancer patients.
All items were scored on 4-point Likert scales ranging
from 1 (not at all) to 4 (very much). As an exception, item
29 and 30 in the global health QOL subscale were scored
on a modified 7 point linear analogue scale. All functional
scales and individual item scores were transformed to a
0–100 scale with higher values indicating a higher func-
tioning in functional scales and an increased presence of
symptoms in symptom scales. Approval was obtained
from EORTC Quality of Life Group. The EORTC QLQ-
BR23 is a 23-item breast cancer-specific questionnaire
about the common side effects of therapy, body image,
sexuality, and outlook for the future. All items were scored
on 4-point Likert scales ranging from 1 (not at all) to 4
(very much). The scoring approach for the QLQ-BR23 is
identical in principle to that for the function and symptom
scales/single items of the QLQ-C30.
Results
The data was analyzed using SPSS 16 software package
with 95 % confidence interval. Descriptive statistics and
t-test was used for subject’s demographic characteristics
(Table 1). The level of significance was set at 0.05. Scores
on each process measure were analyzed with a 2 × 3
mixed model ANOVA, with treatment group (conven-
tional vs. complete decongestive therapy) serving as the
between-subjects factor and time of assessment (base-
line, 4th week and 6th week) serving as the repeated
within-subjects factor. Table 2 shows values of outcome
measures by treatment group and time of measurement.
Pain
There was a significant difference across three time points,
F = 991.96, p < 0.01 (Table 3) and significant differences
between groups, F = 23.82, p < 0.01, in VAS (Table 4).
There was also a significant interaction between time and
group, F = 29.34, p < 0.01. This indicates that there were
significant changes over time in VAS score across all
samples and further analysis of interaction between time
and group shows that changes in VAS over time are not
Table 3 Test of within subjects effects for all outcome measures
F Value










Time 991.96* 120.36* 511.72* 1114.05* 339.71* 13.13*
Time*Group 29.34* 55.91* 120.09* 294.80* 92.87* 2.60*
VAS visual analogue scale, *Statistically significant (p < 0.05)
Table 4 Test of between subjects effects for all measures
Groups Mean(range) (95 % CI) Mean differences (95 % CI) F
VAS CDT 3.81 (3.53–4.10) 0.98 (0.58–1.38) 23.82*
CT 4.79 (4.51–5.07)
EORTC QLQ C30 Global scale CDT 43.54 (41.88–45.21) 2.97 (0.61–5.32) 6.36*
CT 40.58 (38.91–42.24)
EORTC QLQ C30 Functional scale CDT 82.82 (82.26–83.38) 1.94 (1.15–2.74) 24.06*
CT 80.89 (80.32–81.44)
EORTC QLQ C30 Symptoms scale CDT 44.02 (42.81–45.24) 2.10 (0.38–3.82) 6.01*
CT 41.92 (40.71–43.14)
EORTC QLQ BR23 Functional scale CDT 35.57 (34.76–36.37) 2.38 (1.24–3.52) 17.47*
CT 33.19 (32.38–33.99)
EORTC QLQ BR23 Symptoms scale CDT 61.18 (60.14–62.22) 1.52 (0.05–2.10) 4.28*
CT 59.66 (58.61–60.70)
CT conventional therapy, CDT complete decongestive therapy, VAS visual analogue scale, *Statistically significant (p < 0.05)
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equivalent across both the intervention groups (Fig. 1).
Further between test subjects analysis indicates that group
difference in VAS scores averaged across the time was
significant. The estimated marginal means show higher
reduction (M= 4.79) in CDT group than CT group (M=
3.81). The pairwise comparison shows that the mean
difference was high between baseline and 4th week meas-
urement of VAS (3.03) than between 4th week and 6th
week (1.68). So it was inferred that CDT was effective in
reducing the pain in comparison to CT and the time series
repeated measure show that therapy was more effective in
the first four weeks of intervention.
EORTC QLQ C30
The values of QLQ-C30 global health status scale, func-
tional and symptom scales at baseline, 4th and 6th weeks
were represented in Figs. 2, 3 and 4 respectively.
Significant differences were observed across the time
factor for global, functional and symptoms scales of the
EORTC QLQ C30, and F values were 120.36, 511.72 and
1114.05 (p < 0.05) respectively (Table 3). Between groups
factor was significantly different in all these three sub
scales with F value of 6.36 for global scale, 24.06 for
functional scale and 6.01 for symptoms scale at p < 0.01
(Table 4). There was also a significant interaction
between time and group, F = 55.91, 120.09, and 294.80
(p < 0.05) for all the sub scales. The estimated marginal
means show that CDT group had significantly higher im-
provement than the CT group and the pairwise compari-
son shows that the mean difference was high between
baseline and 4th week measurement for all the scales
(4.12, 2.13 and 2.07) than between 4th week and 6th
week (1.63, 1.48 and 1.98).
EORTC QLQ BR 23
Analysis of EORTS QLQ BR 23 measures showed sig-
nificant differences across the time factor for both the
functional and symptoms scales with an F values of
339.71 and 13.13 (p < 0.05) respectively (Table 3). Be-







































Fig. 2 Comparison of QLQ C-30 (Global health status scale) values within and between the groups
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all there three scales with F value of 17.47 for functional
scale and 4.28 for symptoms scale (p < 0.01) (Table 4).
There was also a significant interaction between time
and group, F (2116) = 92.87 and 2.60 for functional and
symptoms scales of the EORTS QLQ BR 23 question-
naire. The estimated marginal means show that CDT
group had significantly higher improvement than the CT
group in all the scales (Figs. 5 and 6). The pairwise com-
parison shows that the mean difference was high be-
tween baseline and 4th week measurement for both the
sub scales (2.58 and 2.33) than between 4th week and
6th week (1.37 and 0.58).
Discussion
The findings of this study indicate that subjects in both
groups showed improvement in pain (VAS) and QOL as
measured by QLQ-C 30 213 and QLQ-BR 23. However,
there was more improvement with CDT and home
program. Comparing the effectiveness of the above
treatment strategies in subjects with post mastectomy
lymphedema (PML), CDT group showed improved
QOL and significant reduction in pain. Greatest re-
duction in pain leading to improved quality of life in
first 4 weeks of treatment, with the effect continuing
at a slower rate in next two weeks. In this study we
found CDT and remedial exercises along with a one
hour home program helped to improve QOL. Kim SJ
et.al [43] studied the effect of complex decongestive
therapy on unilateral lymphedema and quality of life in
breast cancer patients. The results showed that QOL
significantly improved by reduction of upper limb
lymphedema during the maintenance phase, which was
correlated with the reduction in limb volume and sig-
nificant difference in physical functioning and quality
of life as measured by Korean version of SF-36 health
survey [41, 42, 44].
Karadibak D et.al [42] conducted a prospective trial of


























































Fig. 4 Comparison of QLQ C-30 (Symptom scale) values within and between the groups
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lymphedema and showed decrease in edema, fear of ac-
tivity, and improved quality of life. To date, several stud-
ies have been published investigating the effects of CDT
and MLD in preventing and treating post mastectomy
lymphedema [45–51]. Badger et al. [52] in 2004 con-
ducted a randomized clinical trial that tested physical
therapies with a follow-up period of at least 6 months.
They concluded wearing a compression sleeve is benefi-
cial and bandage-plus hosiery resulted in a greater re-
duction in excess limb volume than hosiery alone.
Previous studies on the effectiveness of treatment for
breast cancer related lymphedema found that CDT was
effective but failed to demonstrate the unified approach
to treatment. Most of the study populations are specific
and have methodological limitations such as lesser sample
sizes, lack of control groups etc. Hence, researchers con-
cluded that long term follow up is needed to demonstrate
the relative contribution of individual components such
as compression bandaging, exercises, MLD etc. [53]. In
contrast, our study proved the relative contribution of
remedial exercises and a one hour home program in re-
ducing lymphedema and enhancing QOL. Meneses and
McNees [54] in 2007 cited 86 articles in their review
and showed reduced QOL with lymphedema and con-
cluded that CDT appears to be helpful in treating
lymphedema. Our findings that greater improvement in
the pain, symptoms and function in first 4 weeks than
between 4th and 6th weeks was consistent with another
study showing maximum reductions achieved in first
few days of treatment, with improvement continuing at
a slower rate in the next weeks [55]. Martin et al. [56]
provided information on the effectiveness of MLD and
its impact on the quality of life and physical limitations
among PML patients. They used EORTC QLQ-C30 version
2.0 for cancer in general and EORTC QLQ-BR23 specific
for breast cancer to assess the efficacy of the treatment,
measuring the improvement of the lymphedema. How-


























































Fig. 6 Comparison of QLQ BR-23 (Symptom scale) values within and between the groups
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information on health-related quality of life (HRQOL)
outcomes among post mastectomy lymphedema (PML)
patients is needed. In the present study, EORTC QLQ-C30
version 3.0 for cancer in general and EORTC QLQ – BR 23
specific for breast cancer was used which yielded better re-
sults than the previous study because of inclusion of home
program with emphasis on remedial exercises. It is import-
ant since lymphedema is known to have a significant im-
pact on the physical, psychological, and social well-being of
the patients. In the present study the participants’ cooper-
ation and adherence to home program were high. This may
be due to the attention given to them by the researchers.
Therefore, the present study emphasized the role of remed-
ial exercises and a home program in addition to CDT is
more beneficial in health, function and symptom status of
QOL in post mastectomy lymphedema patients.
Conclusion
Clinically and statistically relevant improvement in QOL
was observed in the CDT group who received remedial
exercises and home program in addition to compression
bandage and manual lymphatic drainage. Therefore, re-
medial exercises and home program should be incorpo-
rated in the treatment protocol of breast cancer related
lymphedema patients.
Limitations of the study
The first limitation of the study was the small sample
size. Secondly, there was no follow up to observe the
long term effects of this technique. Assigning partici-
pants to treatment group based on the day of the week
they are seen in clinic can introduce biases and lack of
random assignment would be a potential limitation of
this study. Future works are required to evaluate the
outcome of a unified plan of treatment in specific popu-
lation for the greater generalizability of the outcomes.
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